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The precise role of factor XII (FXII) in the regulation of blood
coagulation and ﬁbrinolysis is still undeﬁned. Activation of
FXII initiates both the kinin-forming cascade and the intrinsic
coagulation and ﬁbrinolytic pathways. Subjects with severe
FXII deﬁciency show a prolonged activated partial thrombo-
plastin time but do not have a bleeding tendency, which
suggests a minor role for FXII in the regulation of ﬁbrin
formation in vivo. The observation that FXII is also involved in
the activation of the ﬁbrinolytic system led to the hypothesis
that partial or severe FXII deﬁciency might result in impaired
ﬁbrinolysis and as a consequence in a thrombotic tendency.
Indeed, a high frequency (9–15%) of reduced plasma FXII
levels was found among patients with (venous) thrombosis [1,2]
and women with recurrent miscarriages [3], a condition often
associated with a thrombophilic state. However, Koster et al.
showed that the frequency of reduced FXII levels was as high
in control subjects as in patients with venous thrombosis [4].
Other studies failed to ﬁnd an association between partial, and
probably also severe, factor XII deﬁciency and venous
thrombosis in families with hereditary FXII deﬁciency [5–7],
indicating that heterozygous FXII deﬁciency in itself is not a
risk factor for thrombosis.
Recently it was reported that in the families of the GAIT-
study FXII levels exhibited a signiﬁcant positive correlation
with thrombosis, indicating that high FXII levels might
enhance thrombosis risk [8]. Later the same group found
evidence for a quantitative trait locus in F12 which inﬂuenced
both FXII levels and thrombosis risk [9]. A previously reported
polymorphism in the 5¢-untranslated region of the F12 gene
(46 CﬁT) [10], of which the T-allele is associated with reduced
plasma FXII levels [10,11], explained part of the linkage signal
[9]. In a subsequent study Tirado et al. reported a 3-fold
increased risk of venous thrombosis for carriers of the 46TT
genotype (crude OR 3.1; 95% CI 1.1–8.7) and concluded that
the 46T-allele is an independent genetic risk factor for venous
thrombosis in the Spanish population [12]. A previous study
from Franco et al. reported that homozygous 46T carriers did
not have an increased risk of venous thrombosis (OR 0.8, 95%
CI 0.3–1.9) [13]. The reason for the apparent discrepancy
between these two studies may be that both were relatively
small and included only around 15–22 homozygous individu-
als. We studied the effect of the 46CﬁT polymorphism on
plasma FXII levels and thrombosis risk in a large population-
based case–control study on venous thrombosis (Leiden
Thrombophilia Study, LETS). This study, which included
474 patients with a ﬁrst deep vein thrombosis (96% in the leg,
4% in the upper extremities) and 474 control subjects, has been
described previously [14]. Patients (202men, 272 women) had a
mean age of 45 years (range 14–69). In 46% of the patients the
thrombosis was spontaneous, i.e. occurred in the absence of
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risk factors such as surgery, hospital admissions, bed rest
(> 2 weeks), pregnancy and use of oral contraceptives. Overall
the risk factor proﬁle of our patients was very similar to that of
the patients included in the report by Tirado et al. [12], except
that we included ﬁrst events only. The latter may explain the
lower number of individuals with a positive family history in
our study (25% vs. 39% in the study reported by Tirado et al.
[12]).
Blood was collected in 0.1 volume 0.106 mol L)1 trisodium
citrate. Plasma was prepared by centrifugation for 10 min at
2000 g at room temperature and stored at )70 C. FXII
activity was measured using a one-stage clotting assay.
High molecular weight DNA was isolated from leukocytes
and stored at 4 C. Polymerase chain reaction (PCR) was
designed to amplify the region in and around exon 1. The
sequences of the primers were: forward 5¢-GAT AGG CAG
CTG GAC CAA CG-3¢ (nt 21–40 [15]) and reverse 5¢-TGA
TAG CGA CCC CCC AGA AC-3¢ (nt 162–143 [15]). The
ampliﬁed DNA fragments [142 base pairs (bp)] were digested
with Bsa HI, which recognizes a site on the 46C fragment, and
separated by electrophoresis on agarose gels. The 46C-allele is
cut into fragments of 116 bp and 26 bp, while the 46T-allele is
not cut.
The frequency of the 46T-allele was 0.254 in controls and
0.233 in the patients, values similar to those reported previously
in Caucasian populations (0.2–0.28) [10–13]. Among controls
there was an allele-speciﬁc dosage-dependent effect of the
46T-allele on plasma FXII levels [U dL)1, mean (95%CI)]:
46CC (n ¼ 261): 123 (120–125), 46CT (n ¼ 180): 89 (87–92)
and 46 TT (n ¼ 30): 57 (50–63). This conﬁrms previous reports
[11] and indicates that about 5% of the population (the carriers
of the 46TT genotype) have plasma FXII levels identical to
those of heterozygous carriers of a F12 null mutation. This
might explain the high frequency of FXII deﬁciency reported in
earlier studies of uncontrolled groups of patients with throm-
botic disease.
Table 1 shows the frequencies of the 46C/T genotypes in
patients and controls. Odds ratios (OR) were calculated as
estimates of the relative risk by an unmatched method.
Ninety-ﬁve per cent conﬁdence intervals were assessed
according to Woolf [16]. (Homozygous) carriers of the
46T-allele did not have an increased risk of venous throm-
bosis (OR 46TT-carriers 0.82, 95% CI 0.47–1.42). Similar
results were obtained for men and women, and for subjects
> 45 years and £45 years. Our results conﬁrm the ﬁndings
of Franco et al. [13] and differ from those reported by
Tirado et al. [12] In fact, the OR of 0.82 that we observed for
46TT carriers is identical to the one reported by Franco et al.
(OR 0.8), which might even indicate a slight protective effect
of the 46T allele. Such a protective effect would be in
agreement with the previously reported positive correlation of
FXII levels and thrombosis [8]. The reason why Tirado and
coworkers found a crude OR of 3.1 for 46TT carriers is not
known. Among 250 healthy individuals, 90 had the 46CT
and ﬁve the 46TT genotype. This latter number is statistically
the less stable one. When we apply the Hardy–Weinberg
equilibrium equation to the 155 CC and 90 CT carriers,
which numbers are larger and therefore more stable, we can
estimate an allelic prevalence for the 46T allele of 0.225.
Under this allelic prevalence, the expected number of 46TT
carriers is 12.7 (ﬁve observed). In a subsequent study from
the same group the prevalence of the 46T allele among 100
healthy subjects was 0.23 and the number of 46TT carriers
4 (ﬁve expected) [17], indicating that the ﬁnding of Tirado
et al. may be false positive due to the low number of 46TT
genotypes in their sample of the healthy population (see also
[18]). The same considerations might apply to the recent
ﬁnding from the same group that 46TT carriers have a 4-fold
increased risk of ischemic stroke (crude OR of 4.7) [19]. Also
in this study the number of 46TT carriers in the control
population was the less stable ﬁgure (observed 3/231,
expected 8/231).
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A hypercoagulable state in sickle cell disease and beta-
thalassemia is well documented [1,2]. Factor V (FV) Leiden is
the largest inherited risk factor of venous thrombosis [3]. Risks
are estimated to be increased up to 50–100-fold for homo-
zygous adults [4]. In eastern Mediterranean countries, a high
prevelance of FV Leiden was reported in healthy individuals,
with the highest frequency reported in Lebanon (14%) [5,6].
Reduced methylenetetrahydrofolate reducatase (MTHFR)
levels or activity is regarded as a risk factor for deep-vein
thrombosis (DVT) [7]. Lebanon has a relatively high preve-
lance of mutated homozygous (T/T) and heterozygous (C/T)
C677T MTHFR genotypes (11.04% and 39.73%, respect-
ively) [8].
One of our patients with sickle beta-zero thalassemia who
presented with pain in the bilateral shoulder and left knee areas
was diagnosed initially as having sickle cell crisis, but was
shown to have extensive DVT by duplex scanning. Because of
the high frequency of FV Leiden and MTHFR mutations in
our population, these weremeasured and the patient was found
to be homozygous for FV Leiden and heterozygous for the
MTHFR mutation. After treatment with warfarin, the patient
has done well.
To our knowledge, there are no reported cases of sickle beta-
zero thalassemia patients with this proﬁle of inherited throm-
bophilia, making our case the ﬁrst. The high frequency of FV
mutation in our region suggests a role for screening in patients
with sickle beta-thalassemia. Studies are lacking to deﬁne a
prophylactic anticoagulation approach for sickle cell patients
with underlying thrombophilic tendencies. We need to deﬁne
preventive guidelines of sickle beta-thalassemia with thrombo-
philia in the eastern Mediterranean region.
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